to a different RNA species than the 1800 base pair fragment. Therefore, it was concluded that the 1800 base pair fragment represents one cDNA and that the other two fragments together represent another cDNA with an internal EcoRI site.
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The obtained male-specific cDNA was then used as a probe in a Northern blot analysis to investigate the effects of G H at the pretranslational level (Fig. I) . A clear sex difference is seen between the normal male and female which is attenuated after hypophysectomy. Administration of G H in a continuous fashion, thus mimicking the female pattern of G H secretion, caused a complete demasculinization ( = feminization) in both normal and hypophysectomized animals. On the other hand, androgen treatment of female rats, known to cause a masculine profile of G H in serum (Jansson et al., 1985) , caused an increase of the P-4501,, mRNA. Attempts to mimic the male G H pattern by intermittent G H administration did not result in an increase of the specific RNA in this experiment. Screening of the library was then performed with the male specific 1800 base pair fragment as probe. These results indicate that hormonal control of malespecific P-4501,, in rat liver is exerted at a pretranslational level.
While inter-individual variations in drug metabolism and toxicity have been recognized for a number of years, only recently have these differences been addressed in detail.
Several apparent polymorphisms in the oxidation of drugs have been recognized (Mahgoub et al., 1977; Scott & Poffenbarger, 1979; Kupfer & Preisig, 1983; Kleinbloesem et al., 1984; Wedlund et al., 1984) . In each case, a significant fraction of the population (generally about 5%) is deficient in the ability to oxidize a certain drug and may be at risk with regard to potential side effects. Cytochrome P-450 enzymes are involved in these drug oxidations, and we are studying P-450s involved in reactions related to the polymorphisms in order to understand the roles of these enzymes in humans. We have addressed aspects of polymorphic variation in the oxidation of debrisoquine, mephenytoin, nifedipine and tolbutamide, using biochemical probes.
Our earlier studies on the purification of human P-450s had been directed only at the principal enzyme forms that exist in liver (Wang et al., 1980 (Wang et al., , 1983 . More recently we have targeted our approach toward enzymes catalysing specific reactions. The nomenclature which we utilize for the human P-450s is based upon the substrate used to monitor enzyme purification (vide infra); the nomenclature used for rat enzymes involves an acronym for a typical inducer of the P-450 in question (or 'UT' for constitutive protein present in unlreated rats) . P-450,, was purified on the basis of its ability to catalyse debrisoquine 4-hydroxylation and its immunochemical cross-reactivity with rat P-45OUT., (Distlerath & Guengerich, 1984; Distlerath et al., 1985) . In the course of our studies on P-450,, we obtained evidence that phenacetin 0-de-ethylation, which was formerly regarded to be catalysed by the same P-450 as debrisoquine 4-hydroxylation (Boobis et al., 1981) , was actually catalysed by another enzyme. We isolated and characterized this low-K, phenacetin 0-de-ethylase as P-45OP, (Distlerath et al., 1985) . The 4-hydroxylation of S-mephenytoin is catalysed by two enzymes, P-45OMP., and P-45oMp.>, that differ in their apparent monomeric M , values; these two proteins have the same 25 N-terminal amino acid residues and have not been immunochemically distinguishable (Shimada et al., 1986) . P-450N, was purified on the basis of its nifedipine oxidase activity (Guengerich et al., 1986a) . The spectral and electrophoretic properties of these enzymes have been reported, and all of these P-450s are immunochemically distinguishable from each other.
Substrate specificty. The catalytic specificity of the above P-450s has been investigated using techniques of enzyme reconstitution and immunoinhibition. On the basis of studies in vitro in this and other laboratories, P-450,, catalyses debrisoquine 4-hydroxylation, sparteine A5 -oxidation, encainide 0-demethylation, propranolol 4-hydroxylation, bufuralol 1 '-hydroxylation, desmethylimipramine 1 O-hydroxylation, imipramine N-demethylation, dextrometorphan 0-demethylation, and metroprolol a-hydroxylation and 0-demethylation (Distlerath & Guengerich, 1984; Distlerath et al., 1985; Wolff et al., 1985; Birgersson et al., 1986; Gut et al., 1986) . We have also examined a number of other reactions and provided evidence against a role for P-450D, in these (Wolff et al., 1985) . A working model for the active site of the enzyme has been suggested (Wolff et al., 1985) . P-45OP, catalyses low-K, phenacetin 0-de-ethylation (Distlerath et al., 1985) . P-45oNF catalyses the oxidation of nifedipine and a variety of other substituted dihydropyridines, quinidine 3-and N-hydroxylation, the 6P-hydroxylation of testosterone, A4-androstenedione and cortisol, oestradiol 2-and 4-hydroxylation, aldrin epoxidation and benzphetamine demethylation (C. Ged, P. H. Beaune, I . Dalet, P. Maurel & J.-P. Lauroux, unpublished work; Backer & Guengerich, 1986; Guengerich et al., 1986a,b) . P-45OMP catalyses the 4-hydroxylation of S-mephenytoin and S-nirvanol; both P-45OMp.l and P-45oMp.> have similar activities (Shimada et al., 1986) . Studies in vitro suggest that P-45OMP or a very closely related enzyme catalyses the para-(ring) hydroxylation of diphenylhydantoin and the tolyl methyl hydroxylation of the hypoglycaemic agent tolbutamide; however, oxidation of these two compounds does not appear to be reduced in humans who are deficient in mephenytoin 4-hydroxylase activity.
(DNA cloning cDNAs have been isolated from a human liver bacteriophage Agtll library by screening with polyclonal and monoclonal antibodies. A 2500 base pair clone related to f-45oMp has been characterized and the portion corresponding to the protein coding region has been sequenced Vol. 15 (Umbenhauer et al., 1987) . A cDNA clone of similar length related to P-450NF has been characterized and sequenced . Blotting analysis of human liver genomic DNA suggests that these DNAs are parts of multigene families. We have isolated on additional P-450N,-related clone and two additional P-45OMP-related clones from the same cDNA library, which had been prepared from a single individual. A partial length (1300 base pair) cDNA clone related to rat liver P-45ouT.H has been isolated and partially characterized (Churchill et al., 1987) ; this probe recognizes sequences in human liver DNA and mRNA, presumably related to P-450,, .
Orthologous proteins and genes
On the basis of immunochemical studies and sequence comparisons, we have tentatively made the assignments shown in Table I , with caveats related to the existence of multigene families. In some situations, catalytic specificity appears to match sequence similarity and immunochemical cross-reactivity well (e.g. P-450D, and P-45OUT.,). In other cases, the situation is more complex. For instance, rat P-450UT.A and P-45OPcN., both catalyse nifedipine oxidation in rats but in humans only P-45oNF does (Guengerich et a[., 1986a) . Rabbit P-450 1 has characteristic progesterone 21 -hydroxylase and oestradiol 2-hydroxylase activities but human P-45OMP has neither (Umbenhauer et al., 1987) .
Regular ion
Studies in vivo suggest that P-450D, is not inducible and P-450NF is inducible by drugs such as rifampicin, dexamethasone and barbiturates. The limited nature of our samples does not allow us to directly establish whether enzyme induction occurs in vivo. However, human P-450s are somewhat stable in hepatocyte culture under carefully defined conditions (Guillouzo et al., 1985; Ratanasavanh et al., 1986) . We are utilizing antibodies and nucleic acid probes to examine the inducibility of proteins and mRNAs under these conditions. Preliminary experiments indicate that P-45OP, is inducible by 3-methylcholanthrene, P-450N, is inducible by triacetyloleandomycin, and P-45OMP is refractory to all potential inducers tested. We have found that immunoreactive P-45OMP, P-45OMP-related mRNA, and Smephenytoin 4-hydroxylase and tolbutamide hydroxylase activities, are missing in human fetal liver (Crested et al., 1985; Shimada at al., 1986; Umbenhauer et al., 1987) .
Basis of polymorphism
A number of possible explanations can be proposed to account for the variation in catalytic activity which is found in different individuals. We have begun to address some of the possibilities but in no case is the mechanism yet established. We have found a correlation between immunochemically determined P-450N, levels and nifedipine oxidase activity in different liver samples . However, we have not yet been able to clearly demonstrate a correlation between P-450NF-related mRNA levels and either P-45oNF concentration or nifedipine oxidase activity . In the cases of P-450D, and P-45OMP, no relationship has been found at all between mRNA levels, immunochemically detectable protein, and catalytic activity in different liver samples (Distlerath et al., 1985; Shimada et al., 1986; Umbenhauer et al., 1986) . However, rat P-450,,,., , the orthologue of P-450,,, and its activities are well correlated with levels of the 2000 nucleotide mRNA(s) coding for the protein (Churchill et al., 1987) ; this regulatory model does not seem appropriate for humans.
As an alternative to variation in mRNA levels, P-450-related activities may be altered by modifications of structural genes. We are presently examining genomic DNA samples from phenotyped individuals with cDNA and RNA probes to determine if any altered patterns can be related to unusual catalytic activity. In xenobiotic metabolism in the rat, there are several links between the soluble glutathione transferases and enzymes of the cytochrome P-450 mixed-function mono-oxygenase system, such as: ( I ) many electrophiles that result from the oxidation of xenbiotics by cytochrome P-450 enzymes are detoxified by glutathione transferases (for review see Ketterer et al., 1986) ; (2) many of the same agents induce members of both groups of enzymes (e.g. phenobarbitone; for a review see Jakoby & Habig, 1980) . Both enzyme groups are comprised of large numbers of isoenzymes which show marked tissue-specific distribution. Also, both enzyme groups can be subdivided into families which, in the case of glutathione transferases, can be recognized across species (for a review, see Mannervik, 1985) . In all species, the glutathione transferases are dimeric enzymes, the subunits of which have been allotted to families according to the following criteria: amino acid composition, peptide maps, N-terminal sequences, subunit-subunit association, and activities toward a variety of substrates. Hence, subunits 1 and 2, 3 and 4, and 7 have been reported to be products of mutliple genes which fall into three gene families (Beale et ul., 1982 (Beale et ul., , 1983 Mannervik et ul., 1985) . Given such structural relationships, it should be possible to examine in vitro the structure-function relationships of the soluble glutathione transferases, and as a first step toward this aim we shall describe the structural relationships between, and the occurrence of, subunits of the enzymes on the basis of present evidence.
Molecular biology of glutathione transferases

Structural relationships of' the subunits of rat glutathione transferases
In the subunit 1 /2 family, microheterogeneity reported for subunit 1 (Beale et al., 1982) has been confirmed by the characterization of the cDNA sequences containing nucleotide variations (2%) scattered along the coding sequences. Substantial variation also occurs in the 3'non-coding sequences, thereby supporting the interpretation that there are at least two genes encoding subunit 1 polypeptides (Pickett et al., 1984; Lai et al., 1984; Taylor et al., 1984) . For similar reasons subunit 2, which is 90% homologous to subunit 1 at the nucleotide level, can be assumed to be a third member of this gene family (Telakowski-Hopkins et al., 1985) . I t is probable that more members of this multigene family have yet to be identified, given the complexity seen in our Southern blot analysis of restriction enzyme digests of
